Literature DB >> 7680355

Differentiation of human pituitary adenomas determines the pattern of chromogranin/secretogranin messenger ribonucleic acid expression.

L Jin1, W F Chandler, J B Smart, B G England, R V Lloyd.   

Abstract

The distribution of chromogranin/secretogranin (Cg/Sg) mRNAs, determined by Northern and in situ hybridization, was analyzed in 14 cultured pituitary adenomas characterized by immunohistochemistry and hormone secretion in a defined medium in vitro. There were 5 functional GH adenomas, 1 silent GH adenoma, 7 null cell adenomas, and 1 oncocytoma. The null cell adenomas, oncocytoma, and silent GH adenomas were also analyzed by electron microscopy. Most null cell adenomas and the oncocytoma secreted FSH and LH into the culture medium. GH adenomas, which are examples of well differentiated tumors based on morphological examination, expressed significantly more SgIII mRNA compared to the null cell adenomas and oncocytoma (70 +/- 6% vs. 22 +/- 5%; P < 0.001). GH adenomas also expressed significantly less CgA mRNA compared to the less well differentiated null cell adenomas and oncocytoma (27 +/- 6% vs. 67 +/- 4%; P < 0.001), which could be considered less well differentiated based on ultrastructural morphological features. After treatment with phorbol 12-myristate 13-acetate (10(-7) M) for 7 days, there was an increase in the mRNA for CgB and SgII mRNAs in GH and null cell tumors, while dexamethasone treatment for 7 days increased CgA mRNA in GH and null cell adenomas. GnRH treatment for 7 days increased CgB mRNA in null cell adenomas. Phorbol 12-myristate 13-acetate also decreased the percentage of immunoreactive GH cells and GHm RNA, determined by in situ and Northern hybridization analyses. These results indicate that pituitary adenomas have a distinct pattern of Cg/Sg mRNA expression, which appears to be related to the degree of morphological differentiation of these neoplasms, and suggest that the effects of secretagogues on various Cg/Sg mRNA levels may be related to the stimulation of hormone secretion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680355     DOI: 10.1210/jcem.76.3.7680355

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries.

Authors:  L Jin; X Qian; E Kulig; N Sanno; B W Scheithauer; K Kovacs; W F Young; R V Lloyd
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  Chromogranin A transcription and gene expression in Folliculostellate (TtT/GF) cells inhibit cell growth.

Authors:  Gail A Stilling; Jill M Bayliss; Long Jin; Heyu Zhang; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 3.  In situ hybridization: methods and applications.

Authors:  L Jin; R V Lloyd
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

4.  Combined use of 111In-labeled pentetreotide and three-step immunoscintigraphy with antichromogranin A monoclonal antibody in the diagnosis of pituitary adenomas.

Authors:  P Magnani; G Paganelli; A G Siccardi; C Songini; P Colombo; G Faglia; F Fazio
Journal:  Cell Biophys       Date:  1994

5.  Immunoscintigraphy with anti-chromogranin A antibodies in patients with endocrine/neuroendocrine tumors.

Authors:  P Colombo; G Paganelli; P Magnani; C Songini; F Fazio; G Faglia
Journal:  J Endocrinol Invest       Date:  1993-11       Impact factor: 4.256

Review 6.  The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors.

Authors:  P Rosa; H H Gerdes
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

7.  Immunohistochemical evaluation of the post-translational processing of chromogranin A in human pituitary adenomas.

Authors:  A P Heaney; W J Curry; K M Pogue; V L Armstrong; M Mirakhur; B Sheridan; C F Johnston; K D Buchanan; A B Atkinson
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

8.  Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas.

Authors:  H Oka; L Jin; J C Reubi; X Qian; B W Scheithauer; K Fujii; T Kameya; R V Lloyd
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

9.  Chromogranin a processing in human pituitary adenomas and carcinomas: analysis with region-specific antibodies.

Authors:  Long Jin; Shuya Zhang; Jill Bayliss; Bernd Scheithauer; Xiang Qian; Ikuo Kobayashi; Mats Stridsberg; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

10.  Prevalence and Prognostic Significance of Neuroendocrine Differentiation in Colorectal Carcinomas.

Authors:  Ricardo V. Lloyd; Georgene Schroeder; Mitchel D. Bauman; James E. Krook; Long Jin; Richard M. Goldberg; Gist H. Farr
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.